Skip to Content

Recent Publications

Alderson KL, Erbe A, Boyden M, Sondel PM. Clinical development of antibody fusion proteins for cancer therapy. In: Rosenblatt J, Podack E, Barber GN, Ochoa A, eds. Advances in Tumor Immunobiology and Immunotherapy. New York: Springer; 2013: 213-236.

Baiu DC, Brazel CS, Bao Y, Otto M. Interactions of iron oxide nanoparticles with the immune system: challenges and opportunities for their use in nano-oncology. Curr Pharm Des. 2013;19(37):6606-21. PMID: 23621531.

Bhatia R, Rowley HD, Mosher JC, Alsheik NH, Aagaard-Kienitz B, Diamond CD, Iskandar BJ, Peters A, Boriosi JP, Patel NJ. Extensive sinovenous thrombosis and hemorrhagic infarction during therapy for T-cell acute lymphoblastic leukemia. Pediatr Emerg Care. 2013 Jan;29(1):93-7. PMID: 23283276.

Capitini CM, Redmond WL, Shafer-Weaver KA. Professional development session for early career scientists at SITC 2012. J Immunother Cancer 2013:1(6).

Gossai N, Verneris MR, Karras NA, Gorman MF, Patel NJ, Burke MJ. A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD). Bone Marrow Transplant. 2014 Mar;49(3):440-2. Epub 2013 Dec 9. PMID: 24317126.

Hernando D, Cook RJ, Diamond C, Reeder SB. Magnetic susceptibility as a B(0) field strength independent MRI biomarker of liver iron overload. Magn Reson Med. 2013 Jun 25. [Epub ahead of print] PMID: 23801540.

Hoover-Regan M, Becker T, Williams MJ, Shenker Y. Informed consent and research subject understanding of clinical trials. WMJ. 2013 Feb;112(1):18-23. PMID: 23513309.

Lockridge JL, Zhou Y, Becker YA, Ma S, Kenney SC, Hematti P, Capitini CM, Burlingham WJ, Gendron-Fitzpatrick A, Gumperz JE. Mice engrafted with human fetal thymic tissue and hematopoietic stem cells develop pathology resembling chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2013 Sep;19(9):1310-22. Epub 2013 Jun 24. PMID: 23806772.

Maurer BJ, Kang MH, Villablanca JG, Janeba J, Groshen S, Matthay KK, Sondel PM, Maris JM, Jackson HA, Goodarzian F, Shimada H, Czarnecki S, Hasenauer B, Reynolds CP, Marachelian A. Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. Pediatr Blood Cancer. 2013 Nov;60(11):1801-8. Epub 2013 Jun 29. PMID: 23813912.

Qu X, Felder MA, Perez Horta Z, Sondel PM, Rakhmilevich AL. Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model. Int Immunopharmacol. 2013 Dec;17(4):1141-7. Epub 2013 Nov 4. PMID: 24201083.

Shand JC, Qin H, Nasholm N, Capitini CM, Fry TJ. Minor antigen distribution predicts site-specific graft-versus-tumor activity of adoptively transferred, minor antigen-specific CD8 T cells. Biol Blood Marrow Transplant. 2014 Jan;20(1):26-36. Epub 2013 Oct 17. PMID: 24141010.

Van De Voort TJ, Felder MA, Yang RK, Sondel PM, Rakhmilevich AL. Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice. J Immunother. 2013 Jan;36(1):29-40. PMID: 23211623.

Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM. Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival. Cancer Immunol Immunother. 2013 Aug;62(8):1303-13. Epub 2013 May 10. PMID: 23661160.


Last updated: 03/12/2014
webmaster [at] pediatrics [dot] wisc [dot] edu
Copyright © 2014 The Board of Regents of the University of Wisconsin System